AICDA and hematopoietic and lymphoid cell neoplasm: In conclusion, we have shown how the novel mutational signature fitting algorithm mmsig can be applied to identify biologically and clinically important mutational processes acting in hematological cancers, including chemotherapy-related mutational signatures, APOBEC activity in MM and nc-AID in CLL.